Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.

MLA

Oliva, Stefania, et al. “Minimal Residual Disease after Transplantation or Lenalidomide-Based Consolidation in Myeloma Patients: A Prospective Analysis.” Oncotarget, vol. 8, no. 4, Jan. 2017, pp. 5924–35. EBSCOhost, https://doi.org/10.18632/oncotarget.12641.

APA

Oliva, S., Gambella, M., Gilestro, M., Muccio, V. E., Gay, F., Drandi, D., Ferrero, S., Passera, R., Pautasso, C., Bernardini, A., Genuardi, M., Patriarca, F., Saraci, E., Petrucci, M. T., Pescosta, N., Liberati, A. M., Caravita, T., Conticello, C., Rocci, A., … Omedè, P. (2017). Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oncotarget, 8(4), 5924–5935. https://doi.org/10.18632/oncotarget.12641

Chicago

Oliva, Stefania, Manuela Gambella, Milena Gilestro, Vittorio Emanuele Muccio, Francesca Gay, Daniela Drandi, Simone Ferrero, et al. 2017. “Minimal Residual Disease after Transplantation or Lenalidomide-Based Consolidation in Myeloma Patients: A Prospective Analysis.” Oncotarget 8 (4): 5924–35. doi:10.18632/oncotarget.12641.